Entity

Time filter

Source Type

Gurgaon, India

Ranbaxy Laboratories Limited is an Indian multinational pharmaceutical company that was incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in 2008. In 2014, Sun Pharma acquired the entire 63.4% share of Ranbaxy making the conglomerate world’s fifth largest specialty generic pharma company. Ranbaxy exports its products to 125 countries with ground operations in 43 and manufacturing facilities in eight countries. In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. In the Brand Trust Report 2012,Ranbaxy was ranked 161st among India's most trusted brands and subsequently, according to the Brand Trust Report 2013, Ranbaxy was ranked 225th among India's most trusted brands. In 2014 however, Ranbaxy was ranked 184th among India's most trusted brands according to the Brand Trust Report 2014, a study conducted by Trust Research Advisory, a brand analytics company. Wikipedia.


Patent
Ranbaxy Laboratories | Date: 2014-01-06

The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib.


Patent
Ranbaxy Laboratories | Date: 2013-04-10

The present invention relates to a process for the preparation of a cis-intermediate compound of Formula II which is a useful synthetic intermediate for the preparation of tadalafil of Formula Ia potent, selective, and reversible inhibitor of cyclic guanosine 3,5-monophosphate specific phosphodiesterase type 5 enzyme having phosphodiesterase inhibitory activity.


The present invention relates to pure crystalline Form II of an L-malic acid salt of sunitinib and a process for its preparation. The invention further provides crystalline Form II of an L-malic acid salt of sunitinib having a purity of at least 97.0%. The invention also provides crystalline Form II of an L-malic acid salt of sunitinib substantially free of an anti-oxidant. The invention also provides crystalline Form II of L-malic acid salt of sunitinib which remains chemically pure on storage at 25 C.2 C. and 40 C.2 C. at a relative humidity of 60%5% and 75%5%, respectively, for at least 1 month.


Patent
Ranbaxy Laboratories | Date: 2014-12-01

The present invention relates to stable oral pharmaceutical compositions comprising solifenacin or a salt thereof prepared by a double compaction process, wherein the amorphous content of solifenacin or a salt thereof in the composition is not less than 80% by weight. It further relates to a method of treating or preventing overactive bladder syndrome by administering said pharmaceutical compositions.


Patent
Ranbaxy Laboratories | Date: 2013-07-08

The present invention relates to -hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure -hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.

Discover hidden collaborations